Foundationsdeep divesArticle
Andropause: Age-Related Testosterone Change in Men
Learning objectives
- Describe the pattern of age-related testosterone decline: rate, variability, and binding-protein changes.
- Distinguish late-onset hypogonadism from normal aging biochemically and clinically.
- Explain the roles of SHBG and the difference between total and free testosterone.
- Summarize the physiological effects attributed to declining androgens: body composition, bone, mood, sexual function.
- Contrast andropause with menopause in mechanism and magnitude.
A Slope, Not a Cliff
Unlike menopause's relatively abrupt ovarian failure, male androgen decline is gradual: total testosterone falls roughly 1% per year after age 40, with enormous individual variation - many 70-year-olds maintain levels within the young-adult range while some 50-year-olds fall below it. The decline reflects both reduced Leydig-cell function and altered hypothalamic-pituitary signaling, compounded by rising sex hormone-binding globulin (SHBG).
SHBG matters because it determines bioavailability: testosterone bound to SHBG is unavailable to tissues, so as SHBG rises with age, free (bioactive) testosterone falls faster than total testosterone - roughly 2% per year. A 'normal' total testosterone can thus mask functionally low free testosterone. This is why evaluation measures or calculates free testosterone rather than relying on total alone - the physiology that counts is the hormone tissues actually see.
Late-Onset Hypogonadism: When Decline Becomes Disorder
Late-onset hypogonadism (LOH) - sometimes called andropause or 'male menopause' - describes the clinical syndrome of unequivocally low testosterone with compatible symptoms. Biochemically: morning total testosterone below ~300 ng/dL (10.4 nmol/L) on repeated testing, with low or inappropriately normal LH/FSH. Clinically: the diagnostic triad is reduced libido, erectile dysfunction, and decreased morning erections, plus supportive features - fatigue, depressed mood, reduced muscle mass, increased central adiposity, and low bone density.
The key distinction is that LOH is not universal aging but a diagnosable subset: perhaps 2-6% of men in their 40s-70s meet strict criteria, rising with age and strongly associated with obesity and chronic disease (which suppress the axis independently). Symptoms alone are insufficient - fatigue and low libido have countless causes - and testosterone alone is insufficient without symptoms; both are required.
Body Composition, Bone, and Metabolism
Testosterone is anabolic: declining levels shift body composition toward less lean mass and more central fat - a change that itself worsens the picture, because adipose aromatase converts testosterone to estradiol and obesity suppresses gonadotropins, creating a self-reinforcing cycle of lower testosterone and higher fat. Insulin resistance commonly accompanies the shift.
Bone is affected too: testosterone (partly via aromatization to estradiol in bone) supports remodeling balance, and hypogonadal men lose bone density with increased fracture risk - male osteoporosis is underrecognized precisely because the decline is gradual and rarely screened. Erythropoiesis also tracks androgens: testosterone stimulates red cell production, which is why hypogonadism can cause mild anemia and why replacement raises hematocrit - a therapeutic effect that becomes a monitoring parameter.
Mood, Cognition, and Sexual Function
The neurobehavioral correlates of declining testosterone are real but easily overstated. Reduced libido is the most specific sexual symptom; erectile function depends on testosterone permissively but is dominated by vascular and neurological factors - which is why testosterone alone often incompletely restores erections. Mood effects (low energy, irritability, mild depressive symptoms) are reported, though trials show modest and variable benefits of replacement on mood.
Cognitive effects are subtle: some association with spatial and verbal memory, but no dementia-like syndrome - nothing resembling the cognitive signature of hypogonadism is established. The honest summary is that testosterone modulates vitality-related domains (libido, energy, body composition) more than it determines cognition or mood outright, and expectations of replacement should be calibrated accordingly.
Andropause vs Menopause: The Honest Comparison
The term 'male menopause' invites a false equivalence. Menopause is a discrete, universal endocrine event: follicle depletion ends ovarian estrogen production in all women, on a predictable timeline, with a clear hormonal signature. Andropause is a gradual, variable, partial decline affecting a minority clinically - more analogous to a risk factor than an event.
Fertility illustrates the difference: menopause ends female fertility definitively, while spermatogenesis continues (declining in quality) lifelong - older fatherhood remains possible. The comparison that holds is functional, not mechanistic: both transitions involve sex-steroid withdrawal with downstream effects on bone, body composition, mood, and sexual function - but the tempo, universality, and hormonal completeness differ fundamentally.
Evaluation and the Replacement Question
Evaluation follows the physiology: morning total testosterone (circadian peak) on two separate days, with LH/FSH to localize the defect (high gonadotropins suggest testicular failure; low/normal suggest central suppression, often from obesity, illness, or medications like opioids). Prolactin, iron studies, and sleep apnea assessment enter the differential because each can suppress the axis reversibly - treating the cause restores the hormone.
Testosterone replacement is replacement, not enhancement: it is indicated for confirmed hypogonadism with symptoms, aiming for mid-normal levels with monitoring (hematocrit, prostate assessment, cardiovascular context). It is not indicated for normal age-related decline without the syndrome, and supraphysiologic use carries distinct risks. The framework is endocrine restoration - matching treatment to demonstrated deficiency - not anti-aging.
This article overviews androgen physiology for learning. Testosterone testing and any hormone treatment require professional evaluation - self-directed hormone use carries serious cardiovascular, hematologic, and prostate risks.
Key points
- Testosterone declines ~1%/year after 40 (total), ~2%/year free testosterone as SHBG rises - gradual, variable, and incomplete, unlike menopause.
- Free (bioavailable) testosterone, not total alone, reflects tissue exposure; SHBG-bound hormone is inactive.
- Late-onset hypogonadism requires both low morning testosterone (<~300 ng/dL, repeated) and compatible symptoms - neither alone suffices.
- Declining androgens shift body composition (less muscle, more central fat), reduce bone density, and mildly lower erythropoiesis.
- Reduced libido is the most specific symptom; erectile and mood effects are real but multifactorial and modestly testosterone-responsive.
- Obesity suppresses the axis (aromatization, gonadotropin suppression), creating a reversible low-testosterone cycle.
- Evaluation localizes the defect via LH/FSH; reversible causes (medications, apnea, illness) must be excluded before replacement.
Common misconceptions
✓ Truth: Menopause is universal, abrupt, and complete (ovarian failure in all women); testosterone decline is gradual, highly variable, and clinically significant only in a minority. The 'male menopause' label obscures more than it explains.
✓ Truth: Testosterone is permissive for libido and erectile function, but erections are primarily vascular-neurological events. Most age-related ED is vasculogenic; testosterone replacement alone often incompletely restores function.
✓ Truth: Replacement is indicated for confirmed hypogonadism with symptoms - restoring deficiency, not enhancing normal aging. Treating normal age-related levels provides little benefit while adding hematologic, cardiovascular, and prostate considerations.
Frequently asked questions
What is the difference between total and free testosterone?
Total testosterone includes hormone bound to SHBG and albumin; only free (unbound) plus weakly albumin-bound testosterone is bioavailable to tissues. Because SHBG rises with age, free testosterone falls faster than total - making it the more meaningful measure.
How is late-onset hypogonadism diagnosed?
By the combination of repeatedly low morning total testosterone (below ~300 ng/dL) AND compatible symptoms - principally low libido, erectile dysfunction, and reduced morning erections. Either finding alone is insufficient for diagnosis.
Why does obesity lower testosterone?
Adipose tissue aromatizes testosterone to estradiol, and obesity-related inflammation and insulin resistance suppress hypothalamic-pituitary signaling - reducing LH drive to the testes. Weight loss often substantially restores levels.
Does testosterone decline cause male osteoporosis?
It contributes: testosterone (partly via conversion to estradiol in bone) supports remodeling balance, and hypogonadal men show accelerated bone loss. Male osteoporosis is underrecognized because screening focuses on postmenopausal women.